Generic Name and Formulations:
Alosetron (as HCl) 0.5mg, 1mg; tabs.
Prometheus Labs, Inc.
Indications for LOTRONEX:
For women with severe diarrhea-predominant irritable bowel syndrome (IBS) who have chronic IBS symptoms (generally lasting 6 months or longer) and have had anatomic or biochemical abnormalities of the GI tract excluded, and not responded adequately to conventional therapy. Restricted to patients for whom the benefit-to-risk balance is most favorable.
Initially 0.5mg twice daily. May increase to 1mg twice daily after 4 weeks if starting dose is tolerated but inadequate. Discontinue if inadequate control of symptoms after 4 weeks of treatment at 1mg twice daily. If constipation occurs, discontinue until constipation resolves, then restart at 0.5mg once daily. If constipation recurs, discontinue immediately.
Constipation. Intestinal obstruction, stricture. Toxic megacolon. GI perforation, and/or adhesions. Ischemic colitis. Impaired intestinal circulation. Thrombophlebitis. Hypercoagulable state. Crohn's disease. Ulcerative colitis. Diverticulitis. Severe hepatic impairment. Concomitant fluvoxamine.
Serious gastrointestinal adverse reactions.
Discontinue immediately if constipation or symptoms of ischemic colitis develop; may resume if constipation resolves but not if ischemic colitis occurs. Hepatic impairment. Elderly. Debilitated. Pregnancy (Cat.B). Nursing mothers.
5-HT3 receptor antagonist.
See Contraindications. Avoid concomitant moderate CYP1A2 inhibitors (eg, quinolones, cimetidine). May be potentiated by strong CYP3A4 inhibitors (eg, ketoconazole, clarithromycin, telithromycin, protease inhibitors, voriconazole, itraconazole). Caution with drugs that decrease GI motility.
Constipation, abdominal discomfort/pain, nausea, GI discomfort/pain; ischemic colitis, complications of constipation (may be serious).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC